Evidence map›Paper›PMID 39268150›Full record

ArticleJournal of hepatocellular carcinoma2024

Effect of Low-Dose Aspirin Use After Thermal Ablation in Patients with Hepatocellular Carcinoma: A Retrospective Study.

Shanshan Chen, Youjia Duan, Yongchao Zhang, Long Cheng, Liang Cai, Xiaopu Hou, Xiaojun Wang, Wei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shanshan ChenCancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Youjia DuanCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Yongchao ZhangCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Long ChengCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Liang CaiCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Xiaopu HouCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Xiaojun WangDepartment of Integrated Traditional Chinese and Western Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Wei LiCancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0002-9991-7892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To determine the effect of aspirin on hepatocellular carcinoma (HCC) recurrence and survival after thermal ablation. Methods: A retrospective analysis was performed to evaluate the efficacy and safety of aspirin in combination with thermal ablation. The clinical data were collected for the enrolled patients. Progression-free survival (PFS), overall survival (OS), and adverse events were analyzed. Results: A total of 174 patients with HCC were enrolled. The median PFS was 11.1 (95% confidence interval [CI]: 8.1-14.0) months for patients who took aspirin and 8.6 (95% CI: 5.5-11.8) months for patients who did not take aspirin. The median OS of patients in the aspirin group was 76.7 (95% CI: 58.1-95.3) months and that in the non-aspirin group was 53.5 (95% CI: 42.7-64.3) months. In patients with non-viral HCC, OS was significantly better for the aspirin group ( Conclusion: Low-dose aspirin use was associated with better OS in patients with non-viral HCC after thermal ablation. In patients who received thermal ablation alone, the administration of low-dose aspirin could improve PFS. Aspirin use might be a protective factor in some patients after ablation.

Indexed as

aspirinhepatocellular carcinomaretrospective studysurvival analysisthermal ablation

Identifiers

PMID39268150
PMCPMC11391387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.